PCSK9 and familial hypercholesterolemia: Inclisiran treatment did not reduce LDL-C levels (placebo-corrected percentage change in LDL-C level from baseline to day 150 was −1.68% (95% CI: −29.19% to 25.83%; P=0.90) in patients with homozygous familial hypercholesterolemia despite substantial lowering of PCSK9 levels. (placebo-corrected percentage change in PCSK9 levels from baseline to day 150 was −60.6%, p<0.0001)